The Predictive Value of Human Organic Cation Transporter 1 and ABCB1 Expression Levels in Different Cell Populations of Patients with De Novo Chronic Myelogenous Leukemia

Overview

Journal Int J Hematol

Specialty Hematology

Date 2011 Sep 9

PMID 21901397

Citations 7

Authors

Filip Razga

Zdenek Racil

Katerina Machova Polakova

Lucie Buresova

Hana Klamova

Daniela Zackova

Dana Dvorakova

Vaclava Polivkova

Petr Cetkovsky

Jiri Mayer

Affiliations

Soon will be listed here.

Citing Articles

Identification of exosomal microRNAs and related hub genes associated with imatinib resistance in chronic myeloid leukemia.

Karabay A, Ozkan T, Karadag Gurel A, Koc A, Hekmatshoar Y, Sunguroglu A Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(12):9701-9721.

PMID: 38916832 PMC: 11582232. DOI: 10.1007/s00210-024-03198-1.

The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.

Polakova K, Albeer A, Polivkova V, Krutska M, Vlcanova K, Curik N Leukemia. 2023; 38(2):318-325.

PMID: 38129513 PMC: 10844071. DOI: 10.1038/s41375-023-02109-2.

OCT-1 Expression in Patients with Chronic Myeloid Leukemia: A Comparative Analysis with Respect to Response to Imatinib Treatment.

Bozkurt Bulakci B, Aday A, Gurtekin B, Yavuz A, Ozturk S, Cefle K Indian J Hematol Blood Transfus. 2022; 38(4):668-674.

PMID: 36258734 PMC: 9569262. DOI: 10.1007/s12288-022-01532-2.

ABCB1 and BMI1 mRNA expression in patients with chronic myeloid leukemia: impact on imatinib efficacy.

M L Bedewy A, M Elmaghraby S, Kandil N Blood Res. 2019; 54(1):57-62.

PMID: 30956965 PMC: 6439291. DOI: 10.5045/br.2019.54.1.57.

Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia.

Maia R, Vasconcelos F, Souza P, Rumjanek V Molecules. 2018; 23(1).

PMID: 29316665 PMC: 6017716. DOI: 10.3390/molecules23010119.

References

Racil Z, Razga F, Polakova K, Buresova L, Polivkova V, Dvorakova D . Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types. Leuk Lymphoma. 2010; 52(2):331-4. DOI: 10.3109/10428194.2010.533220. View

Hirayama C, Watanabe H, Nakashima R, Nanbu T, Hamada A, Kuniyasu A . Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells. Pharm Res. 2007; 25(4):827-35. DOI: 10.1007/s11095-007-9376-3. View

Racil Z, Razga F, Buresova L, Jurcek T, Dvorakova D, Zackova D . The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population. Am J Hematol. 2010; 85(7):525-8. PMC: 7159453. DOI: 10.1002/ajh.21722. View

Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J . Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27(35):6041-51. PMC: 4979100. DOI: 10.1200/JCO.2009.25.0779. View

Engler J, Zannettino A, Bailey C, Rasko J, Hughes T, White D . OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. Haematologica. 2010; 96(2):213-20. PMC: 3031688. DOI: 10.3324/haematol.2010.033290. View

White D, Dang P, Engler J, Frede A, Zrim S, Osborn M . Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2010; 28(16):2761-7. DOI: 10.1200/JCO.2009.26.5819. View

Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark R . Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther. 2007; 83(2):258-64. DOI: 10.1038/sj.clpt.6100268. View

Bazeos A, Marin D, Reid A, Gerrard G, Milojkovic D, May P . hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia. 2010; 24(6):1243-5. DOI: 10.1038/leu.2010.86. View

White D, Saunders V, Dang P, Engler J, Venables A, Zrim S . Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007; 110(12):4064-72. DOI: 10.1182/blood-2007-06-093617. View

10.

Thomas J, Wang L, Clark R, Pirmohamed M . Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004; 104(12):3739-45. DOI: 10.1182/blood-2003-12-4276. View